Mortality Risk Among Patients With Influenza Illness Admitted to the ICU: A Systematic Review and Meta-Analysis

IF 4.2 4区 医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2025-03-16 DOI:10.1111/irv.70073
Pablo Suárez-Sánchez, Jara Majuelos-Melguizo, Marina Hinojosa-Campos, Bélène Podmore, Iain A. Gillespie, Jennifer Han, Rosa Sloot, Dina Christensen
{"title":"Mortality Risk Among Patients With Influenza Illness Admitted to the ICU: A Systematic Review and Meta-Analysis","authors":"Pablo Suárez-Sánchez,&nbsp;Jara Majuelos-Melguizo,&nbsp;Marina Hinojosa-Campos,&nbsp;Bélène Podmore,&nbsp;Iain A. Gillespie,&nbsp;Jennifer Han,&nbsp;Rosa Sloot,&nbsp;Dina Christensen","doi":"10.1111/irv.70073","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Despite vaccination programs and available treatments, seasonal influenza carries a large mortality burden, especially in intensive care unit (ICU) settings. Understanding the influenza mortality burden in ICU settings can inform treatment planning and resource allocation. Nonetheless, surveillance data on mortality in ICU-admitted patients are scarce and estimates vary greatly. This systematic literature review (SLR) and meta-analysis investigated all-cause mortality risk among ICU-admitted patients with influenza in Europe.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We included observational studies conducted in Europe that reported mortality among patients ≥ 6 months of age with influenza admitted to the ICU. Studies published between January-2009 and December-2019 were included. Quality was assessed using a modified Newcastle-Ottawa scale. Pooled all-cause mortality risk was calculated as a proportion using a random-effects model with an inverse variance method. A sensitivity analysis was also conducted, including only studies identified as having low risk of bias.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirty-seven studies, reporting on 13,616 patients, were included. All-cause mortality ranged from 0% to 67%. The overall pooled mortality risk estimate was 0.24 (95% CI: 0.20, 0.27). Study heterogeneity was high (Cochran's Q test <i>p</i> &lt; 0.01, I<sup>2</sup> = 93%). The sensitivity analysis using only studies identified as having low risk of bias produced a pooled mortality risk of 0.25 (95%CI: 0.21, 0.29).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These results indicate that approximately a quarter of patients with influenza admitted to the ICU die, reinforcing the need for effective vaccination programs and treatment optimization.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70073","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70073","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Despite vaccination programs and available treatments, seasonal influenza carries a large mortality burden, especially in intensive care unit (ICU) settings. Understanding the influenza mortality burden in ICU settings can inform treatment planning and resource allocation. Nonetheless, surveillance data on mortality in ICU-admitted patients are scarce and estimates vary greatly. This systematic literature review (SLR) and meta-analysis investigated all-cause mortality risk among ICU-admitted patients with influenza in Europe.

Methods

We included observational studies conducted in Europe that reported mortality among patients ≥ 6 months of age with influenza admitted to the ICU. Studies published between January-2009 and December-2019 were included. Quality was assessed using a modified Newcastle-Ottawa scale. Pooled all-cause mortality risk was calculated as a proportion using a random-effects model with an inverse variance method. A sensitivity analysis was also conducted, including only studies identified as having low risk of bias.

Results

Thirty-seven studies, reporting on 13,616 patients, were included. All-cause mortality ranged from 0% to 67%. The overall pooled mortality risk estimate was 0.24 (95% CI: 0.20, 0.27). Study heterogeneity was high (Cochran's Q test p < 0.01, I2 = 93%). The sensitivity analysis using only studies identified as having low risk of bias produced a pooled mortality risk of 0.25 (95%CI: 0.21, 0.29).

Conclusions

These results indicate that approximately a quarter of patients with influenza admitted to the ICU die, reinforcing the need for effective vaccination programs and treatment optimization.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ICU住院流感患者的死亡率风险:一项系统回顾和荟萃分析
背景尽管有疫苗接种规划和现有的治疗方法,季节性流感仍带来了巨大的死亡率负担,特别是在重症监护病房(ICU)环境中。了解ICU环境中的流感死亡率负担可以为治疗计划和资源分配提供信息。然而,icu住院患者死亡率的监测数据很少,估计差异很大。本系统文献综述(SLR)和荟萃分析调查了欧洲icu住院流感患者的全因死亡率风险。方法:我们纳入了在欧洲进行的观察性研究,这些研究报告了ICU收治的年龄≥6个月的流感患者的死亡率。纳入了2009年1月至2019年12月期间发表的研究。质量评估采用改良的纽卡斯尔-渥太华量表。合并全因死亡率风险以比例计算,采用随机效应模型和反方差法。还进行了敏感性分析,仅包括确定为具有低偏倚风险的研究。结果纳入37项研究,共13616例患者。全因死亡率从0%到67%不等。总合并死亡风险估计为0.24 (95% CI: 0.20, 0.27)。研究异质性高(Cochran’s Q检验p <; 0.01, I2 = 93%)。仅使用确定为低偏倚风险的研究进行敏感性分析,得出的总死亡风险为0.25 (95%CI: 0.21, 0.29)。这些结果表明,ICU收治的流感患者中约有四分之一死亡,加强了有效疫苗接种计划和治疗优化的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.50%
发文量
120
审稿时长
6-12 weeks
期刊介绍: Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
期刊最新文献
Meeting Report: Fourth Correlates of Protection for Next Generation Influenza Vaccines Issue Information Evaluating COVID-19 Transmission in a Series of Cases and Contacts in Three Municipalities of Colombia: Insights From the WHO First Few X Protocol, August 2020–January 2021 Development and Qualification of a Pseudotyped Virus-Based Microneutralisation Assay for Influenza D Virus. Correspondence About the Paper "Effectiveness of High-Dose Influenza Vaccine Against Hospitalisations in Older Adults (FLUNITY-HD): An Individual Level Pooled Analysis" by Niklas Dyrby Johansen et al., https://doi.org/10.1016/S0140-6736(25)01742-8.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1